论文部分内容阅读
人肺腺癌细胞株SPC-A-1,经抗人正常肺抗血清复被后免疫小鼠,脾细胞和同系NS-1或SP 2/0融合,获得17株单克隆抗体。本文报道其建株过程及其中7株单克隆抗体的一些特征。LAC-122、LAC-163与LAC-210对人体肺腺癌和肺鳞癌的阳性反应率分别为75%、78.3%和75%,除LAC-122对一例胃癌细胞株有微弱交叉反应外,三株单抗对肺小细胞癌, 其它肿瘤组织及正常、胚胎组织均呈阴性。对利用抗体复被瘤细胞及肺癌相关抗原问题作了较详细的讨论.
Human lung adenocarcinoma cell line SPC-A-1 was immunized with anti-human normal lung antiserum, and 17 monoclonal antibodies were obtained by immunizing mice, splenocytes and syngeneic NS-1 or SP 2/0. This article reports the process of its establishment and some of its seven monoclonal antibodies. The positive rates of LAC-122, LAC-163 and LAC-210 on human lung adenocarcinoma and lung squamous cell carcinoma were 75%, 78.3% and 75%, respectively. Except for the weak cross-reaction of LAC-122 to a gastric cancer cell line, Three monoclonal antibodies to small cell lung cancer, other tumor tissues and normal, embryonic tissue were negative. The use of antibody complex tumor cells and lung cancer-related antigen in more detail discussed.